晚期乳腺癌患者孕激素受体状态对芳香化酶抑制剂的疗效和生存的影响

Effect of progesterone receptor status on efficacy of aromatase inhibitors and survival time in patients with advanced breast cancer

本研究主要探讨孕激素受体(PR)对雌激素受体阳性(ER+)和人表皮生长因子受体2(HER-2)阴性晚期乳腺癌患者接受芳香化酶抑制剂(AI)治疗的疗效及无疾病进展时间(PFS)的影响。收集2014年1月至2019年10月河南省肿瘤医院收治的198例晚期乳腺癌患者[均为女性,年龄50(27,80)岁]的临床资料,采用χ^(2)检验对比生存的差异;应用Cox回归模型分析相关预后因素。结果显示,PR+、PR-患者的中位PFS分别为12.5个月和9.0个月,两组生存差异有统计学意义(P=0.004);临床获益(CBR)分别为81.1%和63.1%,差异有统计学意义(P<0.001)。PR+乳腺癌患者的PFS较PR-型乳腺癌患者长,差异有统计学意义(P<0.001)。提示PR是ER+及HER-2阴性患者一线芳AI内分泌治疗的独立预后因素,PR+型较PR-型晚期乳腺癌对一线AI内分泌治疗反应好,PFS时间更长。

To investigate the effect of progesterone receptor(PR)on the efficacy of first-line aromatase inhibitor(AI)endocrine therapy and progression-free survival(PFS)in patients with estrogen receptor(ER)positive HER-2 negative advanced breast cancer.The clinical data of 198 patients with advanced breast cancer treated in Henan Cancer Hospital from January 2014 to October 2019 were collected.The Chi-square test was used to compare the difference between the two groups,and the Cox regression model was used to analyze the related prognostic factors.The median progression-free survival time((PFS))of PR+and PR-patients were 12.5 months and 9.0 months,respectively,and the difference was statistically significant(P=0.004).The clinical benefit rate(CBR)was 81.1%and 63.1%,respectively,and the difference was not statistically significant(P<0.001).PR is an independent prognostic factor of first-line AI endocrine therapy in ER-positive HER-2-negative patients.PR+type breast cancer has a better response to first-line AI endocrine therapy and longer PFS time than PR-type advanced breast cancer.